BPI-371153 / Betta Pharma - LARVOL DELTA

A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Betta Pharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2025 ➔ Apr 2027 | Trial primary completion date: Jun 2024 ➔ Dec 2026

Enrollment open • Trial completion date • Trial primary completion date • Hematological Malignancies • Hepatocellular Cancer • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A first-in-human, phase I study of BPI-371153, a novel small-molecule PD-L1 inhibitor, in advanced solid tumors or recurrent/refractory (r/r) lymphoma (ESMO Asia 2024) - P1 | "Among responsive pts, 3 had positive PD-L1 expression, and one had high TMB. Conclusions BPI-371153 presented manageable safety profile, favorable pharmacokinetics, and encouraging anti-cancer activities in advanced solid tumors or r/r lymphoma."

IO biomarker • Metastases • P1 data • Hematological Malignancies • Hodgkin Lymphoma • Lung Adenocarcinoma • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-1 • PD-L1 • TMB

A Phase 1 Study of BPI-371153 in Subjects With Advanced Solid Tumors or Relapsed/Refractory Lymphoma (clinicaltrials.gov) - P1 | N=110 | Not yet recruiting | Sponsor: Betta Pharmaceuticals Co., Ltd.

IO biomarker • New P1 trial • Hematological Malignancies • Hepatocellular Cancer • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1